-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130

Benzinga·09/28/2026 17:23:08
Listen to the news
B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.